Latest Regulatory News

Kore Potash has raised approximately US$12.2 million through a new share issue to fund critical project payments and maintain working capital for the next year. The fundraise also opens the door for major shareholders to increase their stakes, pending approvals.

St Barbara Limited reports solid progress on its Simberi Expansion Project and Atlantic 15-Mile Processing Hub, with key milestones reached and strategic options under review.

Cuscal Limited has received final regulatory approval from APRA for its full acquisition of Indue Limited, setting the stage for completion by early December.

Talga Group has received a significant A$13.35 million grant from the Swedish Energy Agency to advance its sustainable battery anode manufacturing project, aiming for near-industrial scale validation by mid-2026.

Charter Hall Group reported solid FY25 financial results with significant earnings growth and sustainability milestones, while guiding higher earnings and distributions for FY26.

State Gas Limited has independently certified a maiden 2P gas reserve of 30.2 petajoules at its Rolleston West Project, establishing a solid foundation for a pipeline-connected gas development aimed at the east coast market.

Bubs Australia Limited reported a solid FY25 with $102.5 million revenue and outlined ambitious FY26 guidance targeting up to $125 million, driven by overseas markets and strategic investments.

Renegade Exploration has identified the Myschka prospect in Canada’s Yukon as a promising Reduced Intrusion-Related Gold System, with plans underway for maiden drilling in 2026. High-grade silver, gold, and antimony samples reinforce its potential within the prolific Tombstone Gold Belt.

Cyprium Metals has secured board approval to restart copper cathode production at its Nifty Copper Complex, targeting first output by mid-2026. The plan leverages existing heap leach resources and refurbishes key processing infrastructure to generate near-term cash flow.

ReadCloud Limited reported a 5% revenue increase to $12.9 million for FY25, alongside a 109% surge in underlying EBITDA to $0.76 million, narrowing its statutory loss by 59%. Strong growth in its VET-in-Schools segment and domestic eBooks sales underpinned this improved financial performance.

Amplia Therapeutics has secured positive feedback from the US FDA on its Phase 2b/3 trial design for narmafotinib in pancreatic cancer, paving the way for a late 2026 trial start.

Dalrymple Bay Infrastructure Limited has reaffirmed its position as the world’s largest metallurgical coal export facility with full contracted capacity through 2028 and unveiled detailed plans for a significant terminal expansion.